{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000488","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.157574+00:00","generated_at":"2026-05-24T04:46:53.394931+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vivani Medical Reports Positive Preclinical Data for Once-Yearly Semaglutide Implant NPM-139","bullets":["NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over 91 days.","Data show smooth, non-fluctuating in vivo release and continuous semaglutide exposure, supporting potential for once or twice-yearly dosing.","Vivani's proprietary NanoPortal technology demonstrated versatility beyond exenatide implant NPM-115, with in vitro stability over one year.","First-in-human study LIBERATE-1 for NPM-115 remains on track for top-line data by mid-2025, providing critical information for NPM-139."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000488","json":"https://secwatch.observer/filing/0001753926-25-000488.json","markdown":"https://secwatch.observer/filing/0001753926-25-000488.md","text":"https://secwatch.observer/filing/0001753926-25-000488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625000488/0001753926-25-000488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625000488/vani-20250326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-24T04:46:53.394931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}